Vir Biotechnology IPO
Vir Biotechnology is a clinical-stage immunology company developing treatments for serious infectious diseases and cancer. The company focuses on combining immunologic insights with cutting-edge technologies to develop novel therapeutics that can address global health challenges.
What We Know
Vir Biotechnology went public in October 2019, trading on NASDAQ under the ticker VIR. The company raised approximately $125 million in its IPO, pricing shares at $20 each. The stock gained significant attention during the COVID-19 pandemic due to its antiviral research programs. Vir has partnerships with major companies including GlaxoSmithKline and has continued to advance its pipeline of infectious disease treatments since going public.
Frequently Asked Questions
Has Vir Biotechnology had an IPO?
Yes, Vir Biotechnology completed its IPO in October 2019 and trades publicly on NASDAQ under the ticker VIR. The company has been publicly traded for several years.
When is the Vir Biotechnology IPO date?
Vir Biotechnology already completed its IPO in October 2019. The company is currently publicly traded and does not need another IPO.
How can I buy Vir Biotechnology stock?
You can buy Vir Biotechnology stock through any brokerage account using the ticker symbol VIR on NASDAQ. The stock trades during regular market hours and is available to retail investors.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts